Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Galderma R&D
To assess the efficacy and safety of two concentrations (0.03% and 0.06%) of CD11301 gel in the treatment of early stage CTCL (stage IA, IB, or IIA) versus placebo.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical Diagnosis of CTCL stage IA, IB, or IIA with biopsy within last 3 months
Have BSA involvement corresponding to stages IA, IB or IIA CTCL with at least 3 distinct lesions
You may not be if
CTCL that is stage IIB or great or stage IIA with stage N2 with \>5% circulating Sezary cells or CD8+ or large cell transformation or Progressive CTCL
History of autoimmune disease
Laboratory test values at screening outside of the normal range and judged clinically significant by the investigator
Current participation in another clinical trial of a drug or device or past participation within 4 weeks before Baseline or participant is in exclusion period from a previous clinical trial
Clareo Health | A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
